Augmented Reality and Treadmill Training After Traumatic Brain Injury

January 26, 2022 updated by: Candace Tefertiller, Craig Hospital
Up to 40 participants will be enrolled in this study in order to obtain complete data on 30 participants. The investigators will be assessing if Augmented reality in combination with treadmill training is safe and feasible to use in the clinical environment with participants who have chronic TBI and if there is a signal of effect that this intervention may be more beneficial than treadmill training alone or standard of care.

Study Overview

Study Type

Interventional

Enrollment (Actual)

31

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Colorado
      • Englewood, Colorado, United States, 80113
        • Craig Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Sustained a TBI requiring inpatient rehabilitation
  • > 1 year post TBI
  • 18-65 years of age
  • Not currently participating in any other research study to address balance and gait impairment
  • Not currently participating in physical therapy
  • Ambulates with minimal assistance and/or assistive device
  • Self-report of ongoing balance deficits and mobility deficits
  • Score of 75 or below on CB&M
  • No history of other neurological disorders affecting balance
  • No seizures within the last year
  • No history of psychiatric disorder requiring hospitalization
  • Ability to follow directions and complete standardized instructions

Exclusion Criteria:

- No pregnant or lactating females (Potential female participants will be informed that risks to pregnant or lactating females are unknown; then they will be asked if they are pregnant or lactating, or if they could be pregnant. If there is any uncertainty, they will not be included in the study).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Augmented Reality+ Treadmill training
Participants allocated to this group will receive treadmill training with body weight support (BWS) incorporating augmented feedback games chosen to address clinically perceived deficits using the C-Mill training system.
Augmented Reality (AR) systems are computer-based applications that allow an individual to view a simulated environment and dynamically interact within this environment in real-time. Augmented reality activities will be chosen by the therapist based on the primary deficits assessed during baseline testing.
The goal of each session will be to increase balance and mobility challenge by increasing speed and minimizing BWS. Appropriate BWS will be chosen at the beginning of each training session. Participants will walk for 1 minute on the treadmill at 30%, 20% and 10% BWS. Maximum walking speed will be determined at each level of BWS and the participant will spend the remainder of the session ambulating with BWS at which they were able to achieve maximum walking speed. Additional BWS will be provided up to 30% of the participant's total body weight if the treating therapist identifies safety concerns or unfavorable gait kinematics. If a safe and kinematically appropriate gait pattern is unable to be achieved at up to 30% BWS, the previously determined walking speed will be reduced to achieve a safe and appropriate walking pattern. Participants will be encouraged not to use upper extremity support while ambulating with BWS.
Active Comparator: Treadmill training
Participants allocated to this group will receive treadmill training with body weight support (BWS) using the C-Mill training system.
The goal of each session will be to increase balance and mobility challenge by increasing speed and minimizing BWS. Appropriate BWS will be chosen at the beginning of each training session. Participants will walk for 1 minute on the treadmill at 30%, 20% and 10% BWS. Maximum walking speed will be determined at each level of BWS and the participant will spend the remainder of the session ambulating with BWS at which they were able to achieve maximum walking speed. Additional BWS will be provided up to 30% of the participant's total body weight if the treating therapist identifies safety concerns or unfavorable gait kinematics. If a safe and kinematically appropriate gait pattern is unable to be achieved at up to 30% BWS, the previously determined walking speed will be reduced to achieve a safe and appropriate walking pattern. Participants will be encouraged not to use upper extremity support while ambulating with BWS.
Active Comparator: Over ground training/standard of care
Participants allocated to this group will receive over ground balance and mobility training that would be considered standard of care in outpatient rehabilitation.

Standard of care interventions to address balance and mobility deficits will be chosen from a list of commonly used interventions in outpatient therapy. The goal of each session will be to increase balance and mobility challenge in an over ground condition focusing treatment in the following areas:

  • Biomechanical Constraints
  • Stability Limits
  • Anticipatory Postural Adjustments
  • Reactive Postural Response
  • Sensory Orientation
  • Stability in Gait

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Community Balance and Mobility Scale
Time Frame: Baseline to Week 8
13 activities scored from 0-96, higher numbers reflect greater balance
Baseline to Week 8

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
10 meter walk test
Time Frame: Baseline, Week 4, and Week 8
total time to walk 10 meters
Baseline, Week 4, and Week 8
6 minute walk test
Time Frame: Baseline, Week 4, and Week 8
distance walked in 6 minutes
Baseline, Week 4, and Week 8
Timed Up and Go
Time Frame: Baseline, Week 4, and Week 8
received verbal instructions to stand up from chair, walk 3 meters, cross a line marked on the floor, turn around, walk back and sit down
Baseline, Week 4, and Week 8
Timed Up and Go Cognitive Test
Time Frame: Baseline, Week 4, and Week8
receive verbal instructions to stand up from a chair, walk 3 meters, cross a line marked on the floor, turn around, walk back and sit down while counting backward by threes from a randomly selected number between 20 and 100
Baseline, Week 4, and Week8
Timed Up and Go Manual
Time Frame: Baseline, Week 4, and Week 8
receive verbal instructions to stand up from a chair, walk 3 meters as quickly and safely as possible, cross a lined marked on the floor, turn around, walk back and sit down while holding a cup filled with water
Baseline, Week 4, and Week 8
Activities-Specific Confidence Scale
Time Frame: Baseline, Week 4, and Week 8
16 item measure, scored from 0 to 100. Higher scores reflect great confidence of task
Baseline, Week 4, and Week 8
CNS Vital Signs - Psychomotor Speed Domain
Time Frame: Baseline, Week 4, and Week 8
In-office neurocognitive test that is a non-invasive clinical procedure designed to efficiently and objectively assess a broad spectrum of brain function performance or domains under challenge. Finger tapping test and symbol digit coding will be aggregated to arrive at one reported value representing the psychomotor speed domain. Above average domain scores indicate a standard score (SS) greater than 109 or a Percentile Rank (PR) greater than 74, indicating a high functioning test subject. Average is a SS 90-109 or PR 25-74, indicating normal function. Low Average is a SS 80-89 or PR 9-24 indicating a slight deficit or impairment. Below Average is a SS 70-79 or PR 2-8, indicating a moderate level of deficit or impairment. Very Low is a SS less than 70 or a PR less than 2, indicating a deficit and impairment.
Baseline, Week 4, and Week 8
CNS Vital Signs - Executive Functioning Domain
Time Frame: Baseline, Week 4, and Week 8
In-office neurocognitive test that is a non-invasive clinical procedure designed to efficiently and objectively assess a broad spectrum of brain function performance or domains under challenge. Shifting attention score will represent the executive functioning domain. Above average domain scores indicate a standard score (SS) greater than 109 or a Percentile Rank (PR) greater than 74, indicating a high functioning test subject. Average is a SS 90-109 or PR 25-74, indicating normal function. Low Average is a SS 80-89 or PR 9-24 indicating a slight deficit or impairment. Below Average is a SS 70-79 or PR 2-8, indicating a moderate level of deficit or impairment. Very Low is a SS less than 70 or a PR less than 2, indicating a deficit and impairment.
Baseline, Week 4, and Week 8
CNS Vital Signs - Reaction Time Domain
Time Frame: Baseline, Week 4, and Week 8
In-office neurocognitive test that is a non-invasive clinical procedure designed to efficiently and objectively assess a broad spectrum of brain function performance or domains under challenge. Stroop test score will represent the reaction time domain. Above average domain scores indicate a standard score (SS) greater than 109 or a Percentile Rank (PR) greater than 74, indicating a high functioning test subject. Average is a SS 90-109 or PR 25-74, indicating normal function. Low Average is a SS 80-89 or PR 9-24 indicating a slight deficit or impairment. Below Average is a SS 70-79 or PR 2-8, indicating a moderate level of deficit or impairment. Very Low is a SS less than 70 or a PR less than 2, indicating a deficit and impairment.
Baseline, Week 4, and Week 8
CNS Vital Signs - Cognitive Flexibility Domain
Time Frame: Baseline, Week 4, and Week 8
In-office neurocognitive test that is a non-invasive clinical procedure designed to efficiently and objectively assess a broad spectrum of brain function performance or domains under challenge. Shifting attention test and Stroop test scores will be aggregated to arrive at one reported value representing the cognitive flexibility domain. Above average domain scores indicate a standard score (SS) greater than 109 or a Percentile Rank (PR) greater than 74, indicating a high functioning test subject. Average is a SS 90-109 or PR 25-74, indicating normal function. Low Average is a SS 80-89 or PR 9-24 indicating a slight deficit or impairment. Below Average is a SS 70-79 or PR 2-8, indicating a moderate level of deficit or impairment. Very Low is a SS less than 70 or a PR less than 2, indicating a deficit and impairment.
Baseline, Week 4, and Week 8
Physical Activity Enjoyment Scale
Time Frame: Week 1, Week 2, Week 3, and Week 4
scale of participant enjoyment in the moment. 7-point bipolar rating scale, eleven items are reverse scored. Higher total score reflect greater levels of enjoyment
Week 1, Week 2, Week 3, and Week 4
Global Impression of Change
Time Frame: Week 1, Week 2, Week 3, Week 4, and Week 8
9 point Likert scale. Higher positive score reflects great improvement
Week 1, Week 2, Week 3, Week 4, and Week 8
Heart Rate
Time Frame: Baseline, Week 1, Week 2, Week 3, Week 4, and Week 8
heart rate beats per minute
Baseline, Week 1, Week 2, Week 3, Week 4, and Week 8
Blood Pressure
Time Frame: Baseline, Week 1, Week 2, Week 3, Week 4, and Week 8
systolic and diastolic, mm/Hg
Baseline, Week 1, Week 2, Week 3, Week 4, and Week 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 19, 2020

Primary Completion (Actual)

October 1, 2021

Study Completion (Actual)

October 1, 2021

Study Registration Dates

First Submitted

September 3, 2020

First Submitted That Met QC Criteria

September 11, 2020

First Posted (Actual)

September 18, 2020

Study Record Updates

Last Update Posted (Actual)

January 28, 2022

Last Update Submitted That Met QC Criteria

January 26, 2022

Last Verified

January 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Traumatic Brain Injury

Clinical Trials on Augmented Reality

3
Subscribe